Last reviewed · How we verify
Trivalent Influenza Vaccine intradermal dose — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Trivalent Influenza Vaccine intradermal dose (Trivalent Influenza Vaccine intradermal dose) — Seqirus.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Trivalent Influenza Vaccine intradermal dose TARGET | Trivalent Influenza Vaccine intradermal dose | Seqirus | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Trivalent Influenza Vaccine intradermal dose CI watch — RSS
- Trivalent Influenza Vaccine intradermal dose CI watch — Atom
- Trivalent Influenza Vaccine intradermal dose CI watch — JSON
- Trivalent Influenza Vaccine intradermal dose alone — RSS
Cite this brief
Drug Landscape (2026). Trivalent Influenza Vaccine intradermal dose — Competitive Intelligence Brief. https://druglandscape.com/ci/trivalent-influenza-vaccine-intradermal-dose. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab